AUTL:NSD-Autolus Therapeutics Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 4.5

Change

0.00 (0.00)%

Market Cap

USD 1.20B

Volume

1.44M

Analyst Target

USD 26.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

N/A

USD 130.01B
VRTX Vertex Pharmaceuticals Inc

N/A

USD 123.52B
ARGX argenx NV ADR

N/A

USD 32.41B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 31.68B
MRNA Moderna Inc

N/A

USD 28.23B
BGNE BeiGene Ltd

N/A

USD 20.54B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 17.44B
RPRX Royalty Pharma Plc

N/A

USD 17.14B
UTHR United Therapeutics Corporatio..

N/A

USD 15.72B
INSM Insmed Inc

N/A

USD 12.93B

ETFs Containing AUTL

HOML 8.77 % 0.00 %

N/A

N/A
CLAW 6.09 % 0.95 %

N/A

N/A
PEZ Invesco DWA Consumer Cycl.. 4.44 % 0.60 %

N/A

USD 0.07B
XHB SPDR® S&P Homebuilders E.. 3.46 % 0.35 %

N/A

N/A
TQSM:CA TD Q U.S. Small-Mid-Cap E.. 2.17 % 0.00 %

N/A

CAD 0.19B
RFG Invesco S&P MidCap 400® .. 2.08 % 0.35 %

N/A

N/A
VAMO 1.66 % 0.64 %

N/A

N/A
ZEUS:CA 1.40 % 0.73 %

N/A

N/A
EZM WisdomTree U.S. MidCap Ea.. 1.13 % 0.38 %

N/A

N/A
QVMM Invesco Exchange-Traded F.. 0.60 % 0.00 %

N/A

USD 0.32B
ONEO SPDR® Russell 1000 Momen.. 0.55 % 0.20 %

N/A

N/A
FSMD Fidelity Small-Mid Factor 0.33 % 0.00 %

N/A

USD 0.43B
WLDS:LSE iShares MSCI World Small .. 0.19 % 0.00 %

N/A

N/A
WSML:LSE iShares MSCI World Small .. 0.19 % 0.00 %

N/A

N/A
IUSN:F iShares MSCI World Small .. 0.18 % 0.00 %

N/A

N/A
IUSN:XETRA iShares MSCI World Small .. 0.18 % 0.00 %

N/A

USD 3.82B
WDSC:LSE SPDR MSCI World Small Cap.. 0.18 % 0.00 %

N/A

N/A
WOSC:LSE SPDR MSCI World Small Cap.. 0.18 % 0.00 %

N/A

N/A
ZPRS:F SSgA SPDR ETFs Europe II .. 0.18 % 0.00 %

N/A

USD 0.83B
ZPRS:XETRA SPDR MSCI World Small Cap.. 0.18 % 0.00 %

N/A

USD 0.83B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.12% 37% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.12% 37% F 23% F
Trailing 12 Months  
Capital Gain 49.01% 83% B 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.01% 83% B 91% A-
Trailing 5 Years  
Capital Gain -68.13% 47% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.13% 47% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain -1.53% 56% F 41% F
Dividend Return -1.53% 55% F 37% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 78.88% 35% F 20% F
Risk Adjusted Return -1.95% 56% F 39% F
Market Capitalization 1.20B 82% B 73% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector